Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumor Activity of CD3-Engaging Bispecific Antibodies

Time: 12:00 pm
day: Day Two


– CD3-engaging bispecific antibodies drive potent anti-tumor activity in pre-clinical models as well as in patients
– However, not all patients respond to therapy and many relapse after initially responding
– Here, we describe novel therapeutics that engage alternative T cell signaling pathways and demonstrate combinatorial anti-tumor effects in high-bar pre-clinical models